Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2016

View Archived Issues

AstraZeneca reflects on highlights of fourth quarter 2015

City of Hope develops technology to create cell-permeable antibodies

OncoMed gives update on ALPINE and PINNACLE studies of tarextumab

PharmaMar's phase III lurbinectedin study to continue

Aurinia Pharmaceuticals completes preliminary analysis of AURION study

Innov17 patents retinoid-related orphan receptor ligands

Cisen Pharmaceutical and Medshine Discovery reveal compounds to treat tuberculosis

FDA places full clinical hold on pacritinib

New animal model created for the investigation of glanders

PDS Biotechnology and NCI to codevelop novel cancer immunotherapies

Adaptimmune's NY-ESO T-cell therapy earns FDA breakthrough therapy designation

Sanofi presents milestones of fourth quarter 2015

Study of amifampridine phosphate in MuSK-antibody positive myasthenia gravis begins

Novel fibrinogen mutations are associated with congenital hypofibrinogenemia

VBI and GSK enter vaccine research collaboration

Phase I data support progression of Immune Design's immuno-oncology candidates

Cellceutix plans SPA request for phase III study of brilacidin in ABSSSI

Target for interfering with MYC oncogene activity identified

Merck & Co. files BLA for house dust mite SLIT tablet

Scientists identify unusual mutations in moderate hemophilia B patients

FDA recommends approval of Celltrion's infliximab biosimilar, Epirus advances own biosimilar

BioCryst reports phase II/III results for liquid capsule formulation of avoralstat

Nymox announces results from phase II prostate cancer study

EMA creates Zika virus task force, HemispheRx announces its approach

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...